ES2177638T3 - Uso de mycobacterium para el tratamiento de tumores. - Google Patents

Uso de mycobacterium para el tratamiento de tumores.

Info

Publication number
ES2177638T3
ES2177638T3 ES95913247T ES95913247T ES2177638T3 ES 2177638 T3 ES2177638 T3 ES 2177638T3 ES 95913247 T ES95913247 T ES 95913247T ES 95913247 T ES95913247 T ES 95913247T ES 2177638 T3 ES2177638 T3 ES 2177638T3
Authority
ES
Spain
Prior art keywords
mycobacterium
tumor treatment
immunoregulator
tumors
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913247T
Other languages
English (en)
Inventor
Graham A Rook
John L Stanford
Cynthia Ann Stanford
John Michael Dr Grange
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silence Therapeutics PLC
Original Assignee
Stanford Rook Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Rook Ltd filed Critical Stanford Rook Ltd
Application granted granted Critical
Publication of ES2177638T3 publication Critical patent/ES2177638T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

INVENCION REFERIDA AL USO DE MATERIAL ANTIGENICO Y/O INMUNOREGULADOR DERIVADO DE MYCOBACTERIUM VACCAE PARA RETRASAR O PREVENIR EL CRECIMIENTO O EXTENSION DE TUMORES.
ES95913247T 1994-03-30 1995-03-29 Uso de mycobacterium para el tratamiento de tumores. Expired - Lifetime ES2177638T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9406301A GB9406301D0 (en) 1994-03-30 1994-03-30 Immunotherapeutic agent and its use

Publications (1)

Publication Number Publication Date
ES2177638T3 true ES2177638T3 (es) 2002-12-16

Family

ID=10752750

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913247T Expired - Lifetime ES2177638T3 (es) 1994-03-30 1995-03-29 Uso de mycobacterium para el tratamiento de tumores.

Country Status (22)

Country Link
EP (1) EP0752870B1 (es)
JP (1) JP4135190B2 (es)
KR (1) KR100392582B1 (es)
CN (1) CN1121874C (es)
AP (1) AP9600861A0 (es)
AT (1) ATE218355T1 (es)
AU (1) AU699081B2 (es)
BR (1) BR9507338A (es)
CA (1) CA2186851C (es)
CZ (1) CZ280196A3 (es)
DE (1) DE69526935T2 (es)
DK (1) DK0752870T3 (es)
ES (1) ES2177638T3 (es)
FI (1) FI111223B (es)
GB (1) GB9406301D0 (es)
HU (1) HU220858B1 (es)
NO (1) NO964075L (es)
NZ (1) NZ282863A (es)
PT (1) PT752870E (es)
RU (1) RU2139728C1 (es)
WO (1) WO1995026742A1 (es)
ZA (1) ZA952644B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
JP4358306B2 (ja) * 1996-12-18 2009-11-04 スタンフォード ルーク リミティド 免疫系のＴｈ２活性のダウン−レギュレーションのためのマイコバクテリア・ワクチン
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
WO2003063896A1 (en) * 2002-01-29 2003-08-07 Modi, Rajiv, Indravadan Process of preparing a pharmaceutical composition for immunity against tuberculosis in hiv positive individuals
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
DK1765391T3 (da) * 2004-06-07 2013-03-25 Qu Biolog Inc Bakterielle præparater til behandlingen af cancer
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
BG66067B1 (bg) * 2005-05-18 2011-01-31 Спартак ХАДЖИЕВ Средство с антитуморна активност на база бцж ваксина, метод за неговото получаване и използването му
EP2010216A4 (en) * 2006-03-24 2010-06-09 Donald L Morton MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
SG187201A1 (en) 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
RU2733033C2 (ru) * 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
NO964075L (no) 1996-11-25
NZ282863A (en) 2001-06-29
AP9600861A0 (en) 1996-10-31
CN1150388A (zh) 1997-05-21
AU2078595A (en) 1995-10-23
JP4135190B2 (ja) 2008-08-20
MX9604401A (es) 1997-12-31
PT752870E (pt) 2002-09-30
FI111223B (fi) 2003-06-30
CA2186851A1 (en) 1995-10-12
NO964075D0 (no) 1996-09-27
CA2186851C (en) 2008-11-18
FI963866L (fi) 1996-09-27
WO1995026742A1 (en) 1995-10-12
GB9406301D0 (en) 1994-05-25
CZ280196A3 (en) 1997-02-12
EP0752870B1 (en) 2002-06-05
HUT75835A (en) 1997-05-28
RU2139728C1 (ru) 1999-10-20
ATE218355T1 (de) 2002-06-15
CN1121874C (zh) 2003-09-24
DK0752870T3 (da) 2002-07-15
BR9507338A (pt) 1997-09-16
AU699081B2 (en) 1998-11-19
HU9602661D0 (en) 1996-11-28
KR100392582B1 (ko) 2003-10-30
EP0752870A1 (en) 1997-01-15
JPH09511737A (ja) 1997-11-25
DE69526935D1 (de) 2002-07-11
KR970702057A (ko) 1997-05-13
HU220858B1 (en) 2002-06-29
DE69526935T2 (de) 2002-09-19
FI963866A0 (fi) 1996-09-27
ZA952644B (en) 1996-01-11

Similar Documents

Publication Publication Date Title
ES2177638T3 (es) Uso de mycobacterium para el tratamiento de tumores.
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
ES2055745T3 (es) Compuestos antigestagenicos y antiestrogenos para el tratamiento de tumores hormono-dependientes.
BR9805544C1 (pt) Uso de um composto.
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
SG157951A1 (en) Cripto blocking antibodies and uses thereof
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
EP0709090A3 (en) Compositions for the treatment of resistant tumors
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
EA199900069A1 (ru) Вакцинная композиция против малярии
IT1285770B1 (it) Composti corticoidei
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
PT967987E (pt) Composicoes para o tratamento de tumores contendo extractos de cartilagem de tubarao e agentes antineoplasicos
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
TR199901104T2 (xx) Farmas�tik bile�ikler.
ES2088431T3 (es) Preparacion biologica y su utilizacion.
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
PT977716E (pt) Utilizacao de alcoois como aditivos para rebocos e/ou argamassas
ATE386049T1 (de) Epstein-barr virus type b ctl epitopen
PT853959E (pt) Composicao para o tratamento do amianto
DE69721485D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendungen